Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Immutep.
RELATED STOCKHEAD STORIES
Health & Biotech
Who got what in the healthcare budget, and which ASX stocks could benefit
News
Market Highlights and 5 ASX Small Caps to watch on Wednesday
Health & Biotech
ASX Health Stocks: 2 immunotherapy biotechs announce progress on clinical trials
News
Market Highlights and 5 ASX Small Caps to watch on Thursday
Health & Biotech
ASX Health Stocks: Race Oncology up 8pc on compelling results for kidney cancer drug Zantrene
News
Market Highlights and 5 ASX Small Caps to watch on Thursday
Health & Biotech
ASX Health Stocks: CSL drags Healthcare index down 5pc on a mammoth $6.3bn cap raise
News
Market Highlights and 5 ASX Small Caps to watch on Thursday
Health & Biotech
ScoPo’s Powerplays: Investors look to Healthcare for ESG exposure, and Volpara is the poster child
Health & Biotech
ASX Health Stocks: Apiam and Trajan on acquisition trail, Immutep provides updates on Phase 2 trials
News
Market Highlights and 5 ASX Small Caps to watch on Friday
Health & Biotech
ASX Health Stocks: Mesoblast jumps 10pc on Phase 3 trial results for chronic heart failure
News
Market Highlights and 5 ASX Small Caps to watch on Monday
Health & Biotech
ScoPo’s Powerplays: AGM season ‘flushes out negative surprises’ but creates buying opportunities
News
10 at 10: These ASX stocks are paying off their investors’ excitement this morning
Health & Biotech
China is about to grant patents like never before, and these ASX stocks have already got some
Health & Biotech